Viatris Inc. announced that the U.S. Food and Drug Administration has approved Iron Sucrose Injection, USP, marking the first generic version of Venofer injection to reach the American market. The intravenous iron replacement therapy is indicated for treating iron deficiency anemia in adult and pediatric patients aged 2 years and older with chronic kidney disease.
The approval represents a significant milestone for patients with chronic kidney disease, as iron deficiency anemia is a common complication associated with significantly heightened risk of cardiovascular morbidity and higher mortality rates. The generic product will be available in three single-dose vial strengths: 50 mg/2.5mL, 100mg/5mL, and 200mg/10mL.
Competitive Generic Therapy Designation Provides Market Advantage
The FDA granted Viatris competitive generic therapy designation for the 100 mg/5 mL and 200 mg/10 mL strengths. This regulatory pathway allows for expedited review of generic versions of medications with "inadequate generic competition" and provides eligibility for 180 days of market exclusivity upon commercial launch.
Philippe Martin, Viatris Chief R&D Officer, emphasized the significance of the achievement: "The first FDA approval of a generic iron sucrose is an important advancement for patients with CKD and iron deficiency anemia and a testament to Viatris' advanced technical and manufacturing capabilities. This complex product was developed in-house, and after a number of years working closely with the FDA we are pleased to accomplish this important milestone."
Substantial Market Opportunity
The generic iron sucrose injection enters a substantial market, with the brand-name Venofer recording annual sales of approximately $515 million in the U.S. as of June 30, 2025, according to IQVIA data. Corinne Le Goff, Viatris Chief Commercial Officer, noted that "the U.S. launch of this first-to-market generic iron sucrose will be an important addition to the treatment landscape for chronic kidney disease patients with iron deficiency, and will help increase sustainable access to this critical therapy."
Safety Profile and Clinical Considerations
The approved generic maintains the same safety profile as the reference product. Key safety considerations include monitoring for hypersensitivity reactions, including potentially life-threatening anaphylactic-type reactions that can occur within 30 minutes of infusion completion. Healthcare providers must monitor patients for at least 30 minutes following administration and ensure immediate availability of personnel and therapies to treat serious hypersensitivity reactions.
The most common adverse reactions in adult patients (≥2%) include diarrhea, nausea, vomiting, headache, dizziness, hypotension, pruritus, pain in extremity, arthralgia, back pain, muscle cramp, injection site reactions, chest pain, and peripheral edema. In pediatric patients, the most frequent adverse reactions include headache, respiratory tract viral infection, peritonitis, vomiting, pyrexia, dizziness, cough, nausea, arteriovenous fistula thrombosis, hypotension, and hypertension.
Complex Injectable Pipeline Expansion
This approval strengthens Viatris' position in complex injectable medicines. The company's robust pipeline includes multiple difficult-to-develop and manufacture assets across several therapeutic areas, including ferric carboxymaltose injection, another iron replacement product currently in development.
The iron sucrose injection approval demonstrates Viatris' advanced technical and manufacturing capabilities in developing complex generic medicines that require sophisticated formulation and manufacturing processes to achieve bioequivalence with reference products.
